In recent developments, Morgan Stanley has made adjustments to its price target for Cytek Biosciences (CTKB, Financial), a prominent company in the biosciences sector. As of May 28, 2025, the investment bank has lowered its price target from a previous estimate of $9.00 to a new figure of $7.00. This adjustment reflects a 22.22% decrease in the target valuation.
The analyst overseeing these changes is Tejas Savant, who continues to maintain an "Equal-Weight" rating for Cytek Biosciences (CTKB, Financial). Despite the reduction in the price target, the rating remains unchanged, indicating steady expectations regarding the stock's performance relative to the broader market.
These changes come as part of Morgan Stanley's regular review process, aiming to provide their clients with the most accurate and timely investment insights. The revised price target is indicative of the current market conditions and Cytek Biosciences' (CTKB, Financial) recent performance metrics.
Investors and market watchers will be closely monitoring Cytek Biosciences (CTKB, Financial) following this announcement, as it may influence trading activity and market perception in the short to medium term.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Cytek Biosciences Inc (CTKB, Financial) is $5.20 with a high estimate of $8.00 and a low estimate of $3.00. The average target implies an upside of 109.26% from the current price of $2.49. More detailed estimate data can be found on the Cytek Biosciences Inc (CTKB) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Cytek Biosciences Inc's (CTKB, Financial) average brokerage recommendation is currently 2.7, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Cytek Biosciences Inc (CTKB, Financial) in one year is $9.61, suggesting a upside of 286.72% from the current price of $2.485. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cytek Biosciences Inc (CTKB) Summary page.
